Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NALTREXONE AUGMENTATION OF NEUROLEPTICS IN SCHIZOPHRENIA
Autore:
SERNYAK MJ; GLAZER WM; HENINGER GR; CHARNEY DS; WOODS SW; PETRAKIS IL; KRYSTAL JH; PRICE LH;
Indirizzi:
VA CONNECTICUT HLTH CARE SYST,MENTAL HYG CLIN,NEUROPSYCHIAT PROGRAM,116A1,WESY HAVEN CAMPUS W HAVEN CT 06516 CONNECTICUT MENTAL HLTH CTR,ABRAHAM RIBICOFF RES FACIL,CLIN NEUROSCI RES UNIT NEW HAVEN CT 06519 CONNECTICUT MENTAL HLTH CTR,TREATMENT RES PROGRAM NEW HAVEN CT 00000 VA CONNECTICUT HLTH CARE SYST,SUBSTANCE ABUSE PROGRAM NEW HAVEN CT 00000 YALE UNIV,SCH MED,DEPT PSYCHIAT NEW HAVEN CT 00000 HARVARD UNIV,SCH MED,DEPT PSYCHIAT BOSTON MA 02115 BROWN UNIV,SCH MED,DEPT PSYCHIAT & HUMAN BEHAV PROVIDENCE RI 02912
Titolo Testata:
Journal of clinical psychopharmacology
fascicolo: 3, volume: 18, anno: 1998,
pagine: 248 - 251
SICI:
0271-0749(1998)18:3<248:NAONIS>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALCOHOL DEPENDENCE; OPIATE ANTAGONIST; NALOXONE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
M.J. Sernyak et al., "NALTREXONE AUGMENTATION OF NEUROLEPTICS IN SCHIZOPHRENIA", Journal of clinical psychopharmacology, 18(3), 1998, pp. 248-251

Abstract

This study was conducted to determine whether the addition of naltrexone to ongoing neuroleptic treatment would facilitate the reduction inpositive or negative symptoms in patients with schizophrenia. Twenty-one patients meeting DSM-III criteria for schizophrenia were enrolled;all patients had been stabilized for at least 2 weeks on their dosageof neuroleptic medicine before entering the study. Patients were randomized to receive either placebo or naltrexone 200 mg/day for 3 weeks in addition to their neuroleptic. Patients randomized initially into the placebo arm were crossed over to receive naltrexone in a single-blind fashion for 3 additional weeks. All patients were rated weekly withthe Brief Psychiatric Rating Scale (BPRS). Fifteen patients received placebo and six received naltrexone in the first 3 weeks. No significant effects of naltrexone on total BPRS scores or BPRS subscale scores were observed. Patients who received naltrexone on a single-blind basis at the end of the placebo-controlled trial demonstrated a transient exacerbation in negative symptoms as reflected by the total BPRS scoreand the BPRS Withdrawal-Retardation subscale score. Repeated-measuresanalysis of variance (ANOVA) on the BPRS total Score of the subsequent treatment with naltrexone showed a trend for a significance in the drug by time effect. Repeated-measures ANOVA on the BPRS Withdrawal-Retardation subscale of the subsequent treatment with naltrexone showed asignificant drug by time effect. The current data failed to indicate a clinical benefit when naltrexone was added to the neuroleptic regimen. Other potential applications of naltrexone in schizophrenia are addressed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 09:09:06